Aarti Pharmalabs Limited (AARTIPHARM) - Net Assets
Based on the latest financial reports, Aarti Pharmalabs Limited (AARTIPHARM) has net assets worth Rs19.90 Billion INR (≈ $215.20 Million USD) as of March 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs29.06 Billion ≈ $314.32 Million USD) and total liabilities (Rs9.16 Billion ≈ $99.12 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Aarti Pharmalabs Limited balance sheet quality to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs19.90 Billion |
| % of Total Assets | 68.47% |
| Annual Growth Rate | 512.39% |
| 5-Year Change | 877558.91% |
| 10-Year Change | N/A |
| Growth Volatility | 244561.75 |
Aarti Pharmalabs Limited - Net Assets Trend (2020–2025)
This chart illustrates how Aarti Pharmalabs Limited's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see AARTIPHARM market cap overview.
Annual Net Assets for Aarti Pharmalabs Limited (2020–2025)
The table below shows the annual net assets of Aarti Pharmalabs Limited from 2020 to 2025. Also explore AARTIPHARM shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs19.90 Billion ≈ $215.20 Million |
+13.25% |
| 2024-03-31 | Rs17.57 Billion ≈ $190.02 Million |
+12.74% |
| 2023-03-31 | Rs15.58 Billion ≈ $168.54 Million |
+12.41% |
| 2022-03-31 | Rs13.86 Billion ≈ $149.94 Million |
+611413.49% |
| 2021-03-31 | Rs2.27 Million ≈ $24.52K |
-1.99% |
| 2020-03-31 | Rs2.31 Million ≈ $25.02K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Aarti Pharmalabs Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1323330175100.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs13.23 Billion | 66.50% |
| Common Stock | Rs453.17 Million | 2.28% |
| Other Comprehensive Income | Rs19.45 Billion | 97.72% |
| Total Equity | Rs19.90 Billion | 100.00% |
Aarti Pharmalabs Limited Competitors by Market Cap
The table below lists competitors of Aarti Pharmalabs Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhang Jia Jie Tourism Group Co Ltd
SHE:000430
|
$797.34 Million |
|
Lincoln Educational Services
NASDAQ:LINC
|
$797.80 Million |
|
Wushang Group Co Ltd
SHE:000501
|
$797.82 Million |
|
Peapack-Gladstone Financial
NASDAQ:PGC
|
$797.86 Million |
|
Qt Group Oyj
HE:QTCOM
|
$796.78 Million |
|
Lloyds Banking Group PLC
LSE:LLOY
|
$796.44 Million |
|
Fox Factory Holding Corp
NASDAQ:FOXF
|
$796.32 Million |
|
Newonder Special Electric Co.Ltd
SHE:301120
|
$796.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aarti Pharmalabs Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 17,570,400,000 to 19,899,064,000, a change of 2,328,664,000 (13.3%).
- Net income of 2,724,048,000 contributed positively to equity growth.
- Dividend payments of 317,191,000 reduced retained earnings.
- Other comprehensive income increased equity by 17,589,551,000.
- Other factors decreased equity by 17,667,744,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs2.72 Billion | +13.69% |
| Dividends Paid | Rs317.19 Million | -1.59% |
| Other Comprehensive Income | Rs17.59 Billion | +88.39% |
| Other Changes | Rs-17.67 Billion | -88.79% |
| Total Change | Rs- | 13.25% |
Book Value vs Market Value Analysis
This analysis compares Aarti Pharmalabs Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.70x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 87.86x to 3.70x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-03-31 | Rs9.25 | Rs813.00 | x |
| 2021-03-31 | Rs9.07 | Rs813.00 | x |
| 2022-03-31 | Rs152.99 | Rs813.00 | x |
| 2023-03-31 | Rs171.97 | Rs813.00 | x |
| 2024-03-31 | Rs193.86 | Rs813.00 | x |
| 2025-03-31 | Rs219.44 | Rs813.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aarti Pharmalabs Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.69%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 12.88%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 1.46x
- Recent ROE (13.69%) is above the historical average (4.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -8.08% | 0.00% | 0.00x | 1.08x | Rs-418.32K |
| 2021 | -2.03% | 0.00% | 0.00x | 1.10x | Rs-272.69K |
| 2022 | -0.01% | -0.01% | 0.59x | 1.47x | Rs-1.39 Billion |
| 2023 | 12.42% | 9.95% | 0.87x | 1.44x | Rs376.45 Million |
| 2024 | 12.34% | 11.95% | 0.70x | 1.47x | Rs411.98 Million |
| 2025 | 13.69% | 12.88% | 0.73x | 1.46x | Rs734.14 Million |
Industry Comparison
This section compares Aarti Pharmalabs Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $19,160,073,415
- Average return on equity (ROE) among peers: 18.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aarti Pharmalabs Limited (AARTIPHARM) | Rs19.90 Billion | -8.08% | 0.46x | $797.00 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $83.97 Million | 10.78% | 0.83x | $30.65 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $6.52 Billion | 21.67% | 1.42x | $418.81 Million |
| Abbott India Limited (ABBOTINDIA) | $3.05 Billion | 19.95% | 0.50x | $6.00 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $1.35 Billion | 16.19% | 1.66x | $4.74 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $33.31 Billion | 7.66% | 0.64x | $1.28 Billion |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $6.69 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $183.78 Million | 32.19% | 1.01x | $153.27 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $52.38 Billion | 9.95% | 0.36x | $1.75 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $51.82 Billion | 30.41% | 1.49x | $10.22 Billion |
About Aarti Pharmalabs Limited
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous sys… Read more